Progress and promise

Highlights of the international expert consensus on the primary therapy of early breast cancer 2007

Aron Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thürlimann, H. J. Senn

Research output: Contribution to journalArticle

741 Citations (Scopus)

Abstract

The 10th St Gallen (Switzerland) expert consensus meeting in March 2007 refined and extended a target-oriented approach to adjuvant systemic therapy of early breast cancer. Target definition is inextricably intertwined with the availability of target-specific therapeutic agents. Since 2005, the presence of HER2 on the cell surface has been used as an effective target for trastuzumab much as steroid hormone receptors are targets for endocrine therapies. An expert Panel reaffirmed the primary importance of determining endocrine responsiveness of the cancer as a first approach to selecting systemic therapy. Three categories were acknowledged: highly endocrine responsive, incompletely endocrine responsive and endocrine non-responsive. The Panel accepted HER2-positivity to assign trastuzumab, and noted that adjuvant trastuzumab has only been assessed together with chemotherapy. They largely endorsed previous definitions of risk categories. While recognizing the existence of several molecularly-based tools for risk stratification, the Panel preferred to recommend the use of high-quality standard histopathological assessment for both risk allocation and target identification. Chemotherapy, although largely lacking specific target information, is the only option in cases which are both endocrine receptor-negative and HER2-negative. Chemotherapy is conventionally given with or preceding trastuzumab for patients with HER2-positive disease, and may be used for patients with endocrine responsive disease in cases where the sufficiency of endocrine therapy alone is uncertain. Recommendations are provided not as specific therapy guidelines but rather as a general guidance emphasizing main principles for tailoring therapeutic choice.

Original languageEnglish
Pages (from-to)1133-1144
Number of pages12
JournalAnnals of Oncology
Volume18
Issue number7
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Endocrine Gland Neoplasms
Endocrine System Diseases
Steroid Receptors
Switzerland
Hormones
Guidelines
Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Progress and promise : Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. / Goldhirsch, Aron; Wood, W. C.; Gelber, R. D.; Coates, A. S.; Thürlimann, B.; Senn, H. J.

In: Annals of Oncology, Vol. 18, No. 7, 07.2007, p. 1133-1144.

Research output: Contribution to journalArticle

Goldhirsch, Aron ; Wood, W. C. ; Gelber, R. D. ; Coates, A. S. ; Thürlimann, B. ; Senn, H. J. / Progress and promise : Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. In: Annals of Oncology. 2007 ; Vol. 18, No. 7. pp. 1133-1144.
@article{6970783c2c7c4a6286a4488f29deaac8,
title = "Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007",
abstract = "The 10th St Gallen (Switzerland) expert consensus meeting in March 2007 refined and extended a target-oriented approach to adjuvant systemic therapy of early breast cancer. Target definition is inextricably intertwined with the availability of target-specific therapeutic agents. Since 2005, the presence of HER2 on the cell surface has been used as an effective target for trastuzumab much as steroid hormone receptors are targets for endocrine therapies. An expert Panel reaffirmed the primary importance of determining endocrine responsiveness of the cancer as a first approach to selecting systemic therapy. Three categories were acknowledged: highly endocrine responsive, incompletely endocrine responsive and endocrine non-responsive. The Panel accepted HER2-positivity to assign trastuzumab, and noted that adjuvant trastuzumab has only been assessed together with chemotherapy. They largely endorsed previous definitions of risk categories. While recognizing the existence of several molecularly-based tools for risk stratification, the Panel preferred to recommend the use of high-quality standard histopathological assessment for both risk allocation and target identification. Chemotherapy, although largely lacking specific target information, is the only option in cases which are both endocrine receptor-negative and HER2-negative. Chemotherapy is conventionally given with or preceding trastuzumab for patients with HER2-positive disease, and may be used for patients with endocrine responsive disease in cases where the sufficiency of endocrine therapy alone is uncertain. Recommendations are provided not as specific therapy guidelines but rather as a general guidance emphasizing main principles for tailoring therapeutic choice.",
author = "Aron Goldhirsch and Wood, {W. C.} and Gelber, {R. D.} and Coates, {A. S.} and B. Th{\"u}rlimann and Senn, {H. J.}",
year = "2007",
month = "7",
doi = "10.1093/annonc/mdm271",
language = "English",
volume = "18",
pages = "1133--1144",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Progress and promise

T2 - Highlights of the international expert consensus on the primary therapy of early breast cancer 2007

AU - Goldhirsch, Aron

AU - Wood, W. C.

AU - Gelber, R. D.

AU - Coates, A. S.

AU - Thürlimann, B.

AU - Senn, H. J.

PY - 2007/7

Y1 - 2007/7

N2 - The 10th St Gallen (Switzerland) expert consensus meeting in March 2007 refined and extended a target-oriented approach to adjuvant systemic therapy of early breast cancer. Target definition is inextricably intertwined with the availability of target-specific therapeutic agents. Since 2005, the presence of HER2 on the cell surface has been used as an effective target for trastuzumab much as steroid hormone receptors are targets for endocrine therapies. An expert Panel reaffirmed the primary importance of determining endocrine responsiveness of the cancer as a first approach to selecting systemic therapy. Three categories were acknowledged: highly endocrine responsive, incompletely endocrine responsive and endocrine non-responsive. The Panel accepted HER2-positivity to assign trastuzumab, and noted that adjuvant trastuzumab has only been assessed together with chemotherapy. They largely endorsed previous definitions of risk categories. While recognizing the existence of several molecularly-based tools for risk stratification, the Panel preferred to recommend the use of high-quality standard histopathological assessment for both risk allocation and target identification. Chemotherapy, although largely lacking specific target information, is the only option in cases which are both endocrine receptor-negative and HER2-negative. Chemotherapy is conventionally given with or preceding trastuzumab for patients with HER2-positive disease, and may be used for patients with endocrine responsive disease in cases where the sufficiency of endocrine therapy alone is uncertain. Recommendations are provided not as specific therapy guidelines but rather as a general guidance emphasizing main principles for tailoring therapeutic choice.

AB - The 10th St Gallen (Switzerland) expert consensus meeting in March 2007 refined and extended a target-oriented approach to adjuvant systemic therapy of early breast cancer. Target definition is inextricably intertwined with the availability of target-specific therapeutic agents. Since 2005, the presence of HER2 on the cell surface has been used as an effective target for trastuzumab much as steroid hormone receptors are targets for endocrine therapies. An expert Panel reaffirmed the primary importance of determining endocrine responsiveness of the cancer as a first approach to selecting systemic therapy. Three categories were acknowledged: highly endocrine responsive, incompletely endocrine responsive and endocrine non-responsive. The Panel accepted HER2-positivity to assign trastuzumab, and noted that adjuvant trastuzumab has only been assessed together with chemotherapy. They largely endorsed previous definitions of risk categories. While recognizing the existence of several molecularly-based tools for risk stratification, the Panel preferred to recommend the use of high-quality standard histopathological assessment for both risk allocation and target identification. Chemotherapy, although largely lacking specific target information, is the only option in cases which are both endocrine receptor-negative and HER2-negative. Chemotherapy is conventionally given with or preceding trastuzumab for patients with HER2-positive disease, and may be used for patients with endocrine responsive disease in cases where the sufficiency of endocrine therapy alone is uncertain. Recommendations are provided not as specific therapy guidelines but rather as a general guidance emphasizing main principles for tailoring therapeutic choice.

UR - http://www.scopus.com/inward/record.url?scp=34547852275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547852275&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm271

DO - 10.1093/annonc/mdm271

M3 - Article

VL - 18

SP - 1133

EP - 1144

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -